In previous blog, we described NG25 as a potent dual TAK1 and MAP4K2 inhibitor. The compound shows excellent inhibition for inhibiting IKKβ activation by TLR7 and TLR9 agonists. Today, I’d like to introduce the anti-tumor activity of NG25 in breast cancer. A study from Zhenyu Wang carried out a...